Fresenius, through its operating company Fresenius Kabi, announced today that Epinephrine Injection, USP, is now available in the United States as the first generic version of Epinephrine in a 1mg/1mL vial for U.S. customers. Epinephrine Injection, USP is a prescription medicine used to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock; for emergency treatment of allergic reactions including anaphylaxis and for induction and maintenance of mydriasis during intraocular surgery.
In line with #FutureFresenius, Fresenius Kabi has invested more than $1 billion in recent years to expand and update its U.S. pharmaceutical production as well as distribution facilities. More than 70 percent of the product units shipped in the U.S. by Fresenius Kabi are drugs listed on the FDA’s Essential Medicines List.
